Clinical trial · Interventional
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents
NCT00433459CI-TRIAL-00044280completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| dacarbazine | Drug | Dacarbazine | ALIAS |
| fludeoxyglucose F 18 | Radiation | — | UNRESOLVED |
| prednisolone | Drug | Prednisolone | ALIAS |
| prednisone | Drug | Prednisone | ALIAS |
| procarbazine hydrochloride | Drug | Procarbazine | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- COPP
- description
- procarbazine-containing consolidation chemotherapy arm
- interventionNames
- Drug: cyclophosphamide
- Drug: prednisolone
- Drug: prednisone
- Drug: procarbazine hydrochloride
- Drug: vincristine sulfate
- Radiation: fludeoxyglucose F 18
- Radiation: radiation therapy
- type
- EXPERIMENTAL
- label
- COPDAC
- description
- procarbazine-free consolidation chemotherapy arm
- interventionNames
- Drug: cyclophosphamide
- Drug: dacarbazine
- Drug: prednisolone
- Drug: prednisone
- Drug: vincristine sulfate
- Radiation: fludeoxyglucose F 18
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 17 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed classical Hodgkin's lymphoma * No lymphocyte-predominant Hodgkin's lymphoma * Fine-needle biopsy not sufficient * No prior treatment for Hodgkin's lymphoma except for recommended pre-phase therapy for a large mediastinal tumor PATIENT CHARACTERISTICS: * No known hypersensitivity or contraindication to study drugs * No other current malignancy * No severe concurrent disease (e.g., immune deficiency syndrome) * Not pregnant or nursing * Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment * No known HIV positivity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy or radiotherapy * At least 30 days since prior and no other concurrent investigational drugs or participation in another investigational trial
References
Publications (6)
- DERIVEDKurch L, Landman-Parker J, Georgi TW, Attarbaschi A, Balwierz W, Beishuizen A, Braun M, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fernandez-Teijeiro A, Flerlage JE, Fossa A, Hjalgrim LL, Hraskova A, Karlen J, Klekawka T, Leblanc T, Montravers F, Lopci E, Mascarin M, Pears J, Pelz T, Prelog T, Rohde M, Sabri O, Steglich J, Stoevesandt D, Uytterbroeck A, Vordermark D, Wallace WH, Korholz D, Mauz-Korholz C, Kluge R, Hasenclever D. Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET-Based Response Assessment: Data from the EuroNet-PHL-C1 Trial. J Nucl Med. 2025 Sep 2;66(9):1331-1337. doi: 10.2967/jnumed.125.269603. PMID 40639904
- DERIVEDDaw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, Beishuizen A, Cepelova M, Ceppi F, Fernandez-Teijeiro A, Fossa A, Georgi TW, Hjalgrim LL, Hraskova A, Leblanc T, Mascarin M, Pears J, Landman-Parker J, Prelog T, Klapper W, Ramsay A, Kluge R, Dieckmann K, Pelz T, Vordermark D, Korholz D, Hasenclever D, Mauz-Korholz C. Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):258-267. doi: 10.1001/jamaoncol.2024.5636. PMID 39745682
- DERIVEDPabari R, McCarten K, Flerlage J, Lai H, Mauz-Korholz C, Dieckmann K, Palese M, Kaste S, Castellino SM, Kelly KM, Stoevesandt D, Kurch L. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346. PMID 39058968
- DERIVEDCastellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PMID 37505794
- DERIVEDMauz-Korholz C, Landman-Parker J, Fernandez-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fossa A, Gattenlohner S, Georgi T, Hjalgrim LL, Hraskova A, Karlen J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajic V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Korholz D, Hasenclever D, Wallace WH, Kluge R. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol. 2023 Mar;24(3):252-261. doi: 10.1016/S1470-2045(23)00019-0.